A Phase 3 interventional study of Sitagliptin phosphate and Comparator: placebo to pioglitazone in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-06-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 41st largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 82nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 427 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 55th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 86 in phase 3, and was the 99th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
Drug: Comparator: placebo to Sitagliptin · Drug: Comparator: pioglitazone · Drug: Glimepiride or gliclazide · Drug: Metformin · Drug: Pioglitazone rescue therapy
Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
Drug: Sitagliptin phosphate · Drug: Comparator: placebo to pioglitazone · Drug: Glimepiride or gliclazide · Drug: Metformin · Drug: Pioglitazone rescue therapy
Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
Also known as: Januvia
Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
Also known as: Actos;
Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of metformin; Phase B (Weeks 24- 54): stable dose, as prescribed by investigator, of metformin
Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
Also known as: Actos
Change From Baseline in Hemoglobin A1C (%) at Week 24
Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.
Time frame: Baseline and Week 24
Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54
Time frame: Week 0 to Week 54
Number of Participants Discontinuing Study Drug Due to An Adverse Event
Time frame: Week 0 to Week 54
Change From Baseline in 2-hour Post-Meal Glucose at Week 24
Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Plasma Glucose at Week 24
Change from baseline reflects the Week 24 value minus the baseline value.
Time frame: Baseline to Week 24
| Milestone | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Started | 213 | 214 |
| Completed phase a | 199 | 189 |
| Completed | 172 | 167 |
| Not completed | 41 | 47 |
| Withdrew: Adverse event | 3 | 9 |
| Withdrew: Lack of efficacy | 5 | 4 |
| Withdrew: Lost to follow-up | 6 | 5 |
| Withdrew: Other | 19 | 9 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 19 |
Change from baseline reflects the Week 24 value minus the baseline value. A1C represents the percentage of glycosylated hemoglobin.
| Percentage of glycosylated hemoglobin | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Change From Baseline in Hemoglobin A1C (%) at Week 24 | -0.84 ± 0.82 | -0.16 ± 0.84 |
Change from baseline reflects the Week 24 value minus the baseline value. Two-hour post-meal glucose was measured following a standard meal.
| mg/dL | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Change From Baseline in 2-hour Post-Meal Glucose at Week 24 | -36.8 ± 60.8 | -3.3 ± 67.8 |
Change from baseline reflects the Week 24 value minus the baseline value.
| mg/dL | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 24 | -13.2 (-18.8 to -7.7) | 5.3 (-0.2 to 10.9) |
| participants | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Number of Participants With One or More Adverse Events (AEs) - Week 0 to Week 54 | 120 | 122 |
| participants | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Number of Participants Discontinuing Study Drug Due to An Adverse Event | 3 | 9 |
Collected over Week 0 to Week 54. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin | — | 6/210 (2.9%) | 49/210 (23.3%) |
| Placebo/Pioglitazone | — | 9/212 (4.2%) | 44/212 (20.8%) |
| Event | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| Atrial flutterCardiac disorders | 1/210 | 0/212 |
| CholelithiasisHepatobiliary disorders | 1/210 | 0/212 |
| GangreneInfections and infestations | 1/210 | 0/212 |
| Tooth abscessInfections and infestations | 1/210 | 0/212 |
| Ischaemic strokeNervous system disorders | 1/210 | 0/212 |
| Nasal inflammationRespiratory, thoracic and mediastinal disorders | 1/210 | 0/212 |
| Angina pectorisCardiac disorders | 0/210 | 1/212 |
| Abscess limbInfections and infestations | 0/210 | 1/212 |
| AppendicitisInfections and infestations | 0/210 | 1/212 |
| CellulitisInfections and infestations | 0/210 | 1/212 |
| Event | Sitagliptin | Placebo/Pioglitazone |
|---|---|---|
| HypoglcaemiaMetabolism and nutrition disorders | 38/210 | 31/212 |
| Upper respiratory tract infectionInfections and infestations | 14/210 | 15/212 |
| Age, Continuous(years) | Sitagliptin | Placebo/Pioglitazone | Total |
|---|---|---|---|
| Mean | 54.4 ± 9.6 | 55.4 ± 10.2 | 54.9 ± 9.9 |
| Sex: Female, Male(Participants) | Sitagliptin | Placebo/Pioglitazone | Total |
|---|---|---|---|
| Female | 115 | 114 | 229 |
| Male | 95 | 98 | 193 |
| Hemoglobin A1C(Percentage of glycosylated hemoglobin) | Sitagliptin | Placebo/Pioglitazone | Total |
|---|---|---|---|
| Mean | 8.4 ± 0.8 | 8.4 ± 0.9 | 8.4 ± 0.8 |
| 2-Hour Post-Meal Glucose(mg/dL) | Sitagliptin | Placebo/Pioglitazone | Total |
|---|---|---|---|
| Mean | 240.3 ± 60.6 | 243.3 ± 68.8 | 241.8 ± 64.8 |
| Fasting Plasma Glucose(mg/dL) | Sitagliptin | Placebo/Pioglitazone | Total |
|---|---|---|---|
| Mean | 164.8 ± 40.8 | 165.0 ± 43.9 | 164.9 ± 42.4 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jun 2010 to primary completion in Jul 2011, 13 months.
Results were first posted in Aug 2012, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin